Skip to main content
. 2012 Jan 25;95(3):703–712. doi: 10.3945/ajcn.111.024000

TABLE 2.

Dietary PUFA intake and colorectal polyps stratified by sex

Any adenomatous polyps
Hyperplastic polyps only
Men
Women
Men
Women
Dietary intake Cases/control subjects OR (95% CI)1 Cases/control subjects OR (95% CI)2 Cases/control subjects OR (95% CI)1 Cases/control subjects OR (95% CI)2
n n n n
Linoleic acid
 Q13: Men (range, 3.4–10.6 g/d; median, 8.3 g/d); women (range, 2.1–6.8 g/d; median, 5.6 g/d) 246/343 1.00 (referent) 92/291 1.00 (referent) 75/343 1.00 (referent) 42/291 1.00 (referent)
 Q2: Men (range, 10.7–14.6 g/d; median, 12.7 g/d); women (range, 6.9–9.2 g/d; median, 8.1 g/d) 209/343 0.91 (0.71, 1.18) 86/290 0.95 (0.66, 1.37) 66/343 0.99 (0.67, 1.46) 37/290 0.82 (0.49, 1.36)
 Q3: Men (range, 14.7–18.7 g/d; median, 16.5 g/d); women (range, 9.3–11.8 g/d; median, 10.4 g/d) 204/343 0.88 (0.67, 1.14) 74/290 0.84 (0.58, 1.24) 65/343 1.01 (0.68, 1.50) 33/290 0.73 (0.43, 1.24)
 Q4: Men (range, 18.8–24.7 g/d; median, 21.0 g/d); women (range, 11.9–15.3 g/d; median, 13.2 g/d) 222/343 0.90 (0.69, 1.16) 105/290 1.14 (0.80, 1.64) 74/343 1.10 (0.75, 1.63) 32/290 0.66 (0.39, 1.14)
 Q5: Men (range, 24.8–67.8 g/d; median, 30.4 g/d); women (range, 15.4–48.5 g/d; median, 18.6 g/d) 260/343 1.02 (0.79, 1.31) 99/290 1.08 (0.75, 1.56) 83/343 1.22 (0.83, 1.77) 37/290 0.70 (0.42, 1.19)
P-trend 0.69 0.45 0.81 0.16
Arachidonic acid
 Q1: Men (range, 0–0.053 g/d; median, 0.037 g/d); women (range, 0.0–0.037 g/d; median, 0.027 g/d) 229/343 1.00 (referent) 100/291 1.00 (referent) 71/343 1.00 (referent) 39/291 1.00 (referent)
 Q2: Men (range, 0.054–0.079 g/d; median, 0.066 g/d); women (range, 0.038–0.056 g/d; median, 0.047 g/d) 200/343 0.95 (0.73, 1.23) 91/290 0.90 (0.64, 1.28) 56/343 0.85 (0.57, 1.27) 38/290 1.09 (0.65, 1.82)
 Q3: Men: range, 0.080–0.109 g/d; median, 0.093 g/d); women (range, 0.057–0.077 g/d; median, 0.067 g/d) 251/343 1.18 (0.91, 1.53) 82/290 0.83 (0.58, 1.19) 92/343 1.30 (0.90, 1.89) 25/290 0.73 (0.41, 1.28)
 Q4: Men (range, 0.110–0.159 g/d; median, 0.131 g/d); women (range, 0.078–0.107 g/d; median, 0.090 g/d) 223/343 1.01 (0.78, 1.31) 94/290 0.94 (0.66, 1.34) 72/343 1.01 (0.68, 1.49) 44/290 1.32 (0.80, 2.19)
 Q5: Men (range, 0.160–1.23 g/d; median, 0.214 g/d); women (range, 0.108–0.433 g/d; median, 0.139 g/d) 238/343 0.95 (0.73, 1.22) 89/290 0.83 (0.59, 1.18) 72/343 0.92 (0.63, 1.35) 35/290 0.98 (0.59, 1.64)
P-trend 0.46 0.40 0.85 0.81
α-Linolenic acid
 Q1: Men (range, 0.3–0.9 g/d; median, 0.8 g/d); women (range, 0.1–0.5 g/d; median, 0.4 g/d) 218/343 1.00 (referent) 78/291 1.00 (referent) 60/343 1.00 (referent) 32/291 1.00 (referent)
 Q2: Men (range, 1.0–1.2 g/d; median, 1.1 g/d); women (range, 0.6–0.7 g/d; median, 0.7 g/d) 222/343 1.04 (0.81, 1.35) 86/290 1.15 (0.79, 1.67) 73/343 1.31 (0.88, 1.95) 35/290 1.15 (0.67, 1.99)
 Q3: Men (range, 1.3–1.6 g/d; median, 1.4 g/d); women (range, 0.8–0.9 g/d; median, 0.8 g/d) 195/343 0.91 (0.70, 1.19) 74/290 0.95 (0.64, 1.42) 61/343 1.10 (0.73, 1.67) 30/290 0.88 (0.49, 1.57)
 Q4: Men (range, 1.7–2.1 g/d; median, 1.9 g/d); women (range, 0.9–1.2 g/d; median, 1.1 g/d) 222/343 0.98 (0.75, 1.28) 113/290 1.46 (1.00, 2.14) 72/343 1.28 (0.85, 1.92) 39/290 1.23 (0.70, 2.15)
 Q5: Men (range, 2.2–6.7 g/d; median, 2.7 g/d); women (range, 1.3–4.6 g/d; median, 1.5 g/d) 284/343 1.11 (0.87, 1.43) 105/290 1.34 (0.92, 1.96) 97/343 1.51 (1.03, 2.21) 45/290 1.24 (0.73, 2.11)
P-trend 0.09 0.12 0.03 0.57
Marine-derived n−3 PUFAs4
 Q1: Men (range, 0.00–0.042 g/d; median, 0.022 g/d); women (range, 0.0–0.023 g/d; median, 0.012 g/d) 268/343 1.00 (referent) 106/291 1.00 (referent) 83/343 1.00 (referent) 38/291 1.00 (referent)
 Q2: Men (range, 0.043–0.082 g/d; median, 0.063 g/d); women (range, 0.024–0.051 g/d; median, 0.037 g/d) 217/343 0.96 (0.74, 1.24) 96/290 1.01 (0.71, 1.43) 86/343 1.29 (0.89, 1.87) 34/290 1.09 (0.63, 1.87)
 Q3: Men (range, 0.083–0.140 g/d; median, 0.111 g/d); women (range, 0.052–0.087 g/d; median, 0.067 g/d) 218/343 0.99 (0.76, 1.28) 98/290 0.98 (0.69, 1.40) 60/343 0.90 (0.61, 1.35) 37/290 1.26 (0.74, 2.26)
 Q4: Men (range, 0.141–0.246 g/d; median, 0.179 g/d); women (range, 0.088–0.140 g/d; median, 0.107 g/d) 227/343 1.03 (0.80, 1.32) 88/290 0.89 (0.62, 1.27) 80/343 1.24 (0.86, 1.81) 52/290 1.76 (1.06, 2.91)
 Q5: Men (range, 0.247–3.883 g/d; median, 0.342 g/d); women (range, 0.141–1.01 g/d; median, 0.232 g/d) 211/343 0.94 (0.73, 1.21) 68/290 0.67 (0.47, 0.97) 54/343 0.83 (0.56, 1.24) 20/290 0.68 (0.38, 1.23)
P-trend 0.18 0.01 0.12 0.27
Ratio of total n−6 to marine-derived n−3 PUFAs
 Q1: Men (range, 6–71; median, 50); women (range, 7–71; median, 49) 199/343 1.00 (referent) 95/291 1.00 (referent) 60/343 1.00 (referent) 32/291 1.00 (referent)
 Q2: Men (range, 72–117; median, 92); women (range, 72–120; median, 93) 215/343 1.01 (0.78, 1.31) 85/290 0.98 (0.69, 1.40) 65/343 1.12 (0.75, 1.68) 44/290 1.34 (0.80, 1.25)
 Q3: Men (range, 118–187; median, 142); women (range, 121–210; median, 158) 232/343 1.08 (0.82, 1.42) 65/290 0.74 (0.50, 1.09) 70/343 1.18 (0.77, 1.78) 34/290 0.86 (0.49, 1.53)
 Q4: Men (range, 188–389; median, 256); women (range, 211–42; median, 289) 226/343 0.92 (0.68, 1.25) 94/290 1.09 (0.73, 1.63) 72/343 1.12 (0.71, 1.75) 33/290 0.84 (0.45, 1.56)
 Q5: Men (range, 390–78,588; median, 713); women (range, 428–118,125; median, 848) 269/343 0.95 (0.67, 1.34) 117/290 1.30 (0.88, 1.92) 96/343 1.38 (0.83, 2.28) 38/290 0.81 (0.43, 1.54)
P-trend 0.18 0.04 0.79 0.27
1

Adjusted for age, race, BMI, total energy intake, smoking status, alcohol use, study site, educational status, physical activity, family history of colorectal neoplasm, indication for colonoscopy, year of study, calcium intake, and aspirin use.

2

Adjusted for age, race, BMI, total energy intake, smoking status, alcohol use, study site, educational status, physical activity, family history of colorectal neoplasm, indication for colonoscopy, year of study, calcium intake, aspirin use, and hormone replacement therapy.

3

Q, quintile.

4

EPA + docosapentanoic acid + DHA.